GlassScriptPhysician profile
Dipali Trivedi
NPI 1407055973
$14,696.59
in general payments reported to CMS, 2019-2025
51 companies · $2,946 in 2025
The $2,946 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $107 · 2021: $111 · 2022: $32.31 · 2023: $24.90 · 2024: $645 · 2025: $2,946.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,616.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,616.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tosoh Bioscience, INC. | $10,812.00 | 2019 | |
| Merck Sharp & Dohme LLC | $300.01 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Astellas Pharma US INC | $282.11 | 2020-2025 | Vyloy, Xtandi, Padcev |
| Celgene Corporation | $281.96 | 2024-2025 | Reblozyl, Opdualag, Pomalyst |
| Abbvie INC. | $264.96 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $237.67 | 2022-2025 | |
| Janssen Biotech, INC. | $232.12 | 2024-2025 | Rybrevant, Erleada, Balversa |
| Astrazeneca Pharmaceuticals LP | $137.71 | 2024-2025 | Calquence, Enhertu |
| Eisai INC. | $126.80 | 2024-2025 | |
| Genzyme Corporation | $121.50 | 2024-2025 | |
| Beone Medicines USA, INC. | $120.36 | 2025 | Tevimbra, Brukinsa |
| Dova Pharmaceuticals | $110.60 | 2021 | |
| Pfizer INC. | $108.08 | 2024-2025 | |
| Incyte Corporation | $100.35 | 2024-2025 | Zynyz, Monjuvi, Jakafi |
| Daiichi Sankyo INC. | $97.96 | 2020-2025 | Enhertu |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dipali Trivedi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.